{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:13:34Z","timestamp":1790054014476,"version":"4.0.1"},"reference-count":52,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2010,6,17]],"date-time":"2010-06-17T00:00:00Z","timestamp":1276732800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[2010,10]]},"abstract":"<jats:p>Glioblastoma treatment as now constituted offers increased survival measured in months over untreated patients. Because glioblastomas are active in synthesizing a bewildering variety of growth factors, a systematic approach to inhibiting these is being undertaken as treatment adjunct. The serotonin 7 receptor is commonly overexpressed in glioblastoma. Research documentation showing agonists at serotonin receptor 7 cause increased extracellular regulated kinase 1\/2 activation, increased interleukin\u20106 synthesis, increased signal transducer and activator of transcription\u20103 activation, increased resistance to apoptosis and other growth enhancing changes in glioblastoma is reviewed in this paper. Because three drugs in wide use to treat thought disorders \u2013 paliperidone, pimozide and risperidone \u2013 are also potent and well\u2010tolerated inhibitors at serotonin receptor 7, these drugs should be studied for growth factor deprivation in an adjunctive role in glioblastoma treatment.<\/jats:p>","DOI":"10.1111\/j.1476-5381.2010.00923.x","type":"journal-article","created":{"date-parts":[[2010,6,17]],"date-time":"2010-06-17T08:35:46Z","timestamp":1276763746000},"page":"481-487","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Glioblastoma chemotherapy adjunct via potent serotonin receptor\u20107 inhibition using currently marketed high\u2010affinity antipsychotic medicines"],"prefix":"10.1111","volume":"161","author":[{"given":"RE","family":"Kast","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,9,3]]},"reference":[{"issue":"1","key":"e_1_2_10_2_1","first-page":"S1","article-title":"Guide to Receptors and Channels (GRAC)","volume":"158","author":"Alexander SPH","year":"2009","journal-title":"Br J Pharmacol"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23407"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-07-2180"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1593\/tlo.09274"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005706019048"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2004.11.017"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1014467626314"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2393"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2010.01.009"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1998.71051837.x"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2008.03.020"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0700921"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601646"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0192-0561(00)00046-1"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2005.05.006"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02685897"},{"key":"e_1_2_10_18_1","first-page":"408","article-title":"Why cerebellar glioblastoma is rare and how that indicates adjunctive use of the FDA approved antiemetic aprepitant might retard cerebral glioblastoma growth: a new hypothesis answering an old question. Clin Transl","volume":"11","author":"Kast RE","year":"2009","journal-title":"Oncology"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2009.01148.x"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.3923\/ijcr.2006.303.314"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-9-27"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.3171\/2008.12.JNS081284"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2005.03079.x"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00305.2008"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-010-0158-0"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20871"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.2174\/187152009788680019"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1789.2008.00911.x"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0705936"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.28.10.1283"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2008.04.029"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.6.5.803"},{"key":"e_1_2_10_33_1","first-page":"221","article-title":"The role of pimozide in clinical psychiatry: a review","volume":"52","author":"Opler LA","year":"1991","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_10_34_1","first-page":"29","article-title":"Extrapyramidal side effects and tolerability of risperidone: a review","volume":"55","author":"Owens DG","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.2174\/138955707781662663"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2005.04.024"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206047"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-006-0611-0"},{"key":"e_1_2_10_39_1","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0022-3565(25)38596-4","article-title":"Binding of typical and atypical antipsychotic agents to 5\u2010hydroxytryptamine\u20106 and 5\u2010hydroxytryptamine\u20107 receptors","volume":"268","author":"Roth BL","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-007-9517-3"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2009.03.011"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02478920"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.106.024612"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700824"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1480007"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0712034105"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.259"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2001.1942"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.2174\/1568007043482633"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-199303000-00019"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M108347200"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.307"},{"key":"e_1_2_10_53_1","first-page":"119","article-title":"Rho\/ROCK and MAPK signaling pathways are involved in glioblastoma cell migration and proliferation","volume":"29","author":"Zohrabian VM","year":"2009","journal-title":"Anticancer Res"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1476-5381.2010.00923.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1476-5381.2010.00923.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T01:25:50Z","timestamp":1740187550000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1476-5381.2010.00923.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,3]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["10.1111\/j.1476-5381.2010.00923.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1476-5381.2010.00923.x","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,3]]},"assertion":[{"value":"2010-09-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}